In order to assess the dynamics of bone turnover during menopausal transition, we measured the urinary excretion of C-telopeptide (CTX) and N-telopeptide (NTX) of type-I collagen, new markers of bone resorption, using two ELISAs which recognize the corresponding cross-linked peptide of type-I collagen. CTX and NTX levels in postmenopausal women were significantly higher than those in premenopausal women, confirming the enhancement of bone resorption after menopause. The measurement of CTX and NTX, which is convenient and specific for bone resorption compared with conventional bone resorption markers, pyridinoline and deoxypyridinoline, might be useful in the management of postmenopausal women.

Keywords:
C-Telopeptide, N-Telopeptide, Bone resorption, Menopause
1.
Gertz BJ, Shao P, Hanson DA, Quan H, Harris ST, Genant HK, Chesnut CH III, Eyre DR: Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptide in urine. J Bone Miner Res 1994;9:135–142.
2.
Garnero P, Gineyts E, Riou JP, Delmas PD: Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994;79:780–785.
3.
Hanson DA, Weis MAE, Bollen A-M, Maslan SL, Singer FR, Eyre DR: A specific immunoassay for monitoring human bone resorption: Quantitation of type-I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251–1258.
4.
Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C: Evaluation of an immunoassay for quantitation of type-I collagen degradation products in urine. Clin Chem 1994;40:2022–2025.
5.
Uebelhart D, Shelemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD: Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991;72:367–373.
6.
Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD: Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995;10:641–649.
7.
Sone T, Miyake M, Takeda N, Fukunaga M: Urinary excretion of type-I collagen crosslinked N-telopeptides in healthy Japanese adults: Age- and sex-related changes and reference limits. Bone 1995;17:335–339.
8.
Ravn P, Fledelius C, Rosenquist C, Overgaard K, Christiansen C: High bone turnover is associated with low bone mass in both pre- and postmenopausal women. Bone 1996;19:291–298.
9.
Ebeling PR, Atley LM, Guthrie JR, Burger HG, Dennerstein L, Hopper JL, Wark JD: Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab 1996;81:3366–3371.
10.
Hassager C, Colwell A, Assiri AMA, Eastell R, Russell RGG, Christiansen C: Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: A longitudinal and cross-sectional study. Clin Endocrinol 1992;37:45–50.
11.
Uebelhart D, Gineyts E, Chapuy MC, Delmas PD: Urinary excretion of pyridinium crosslinks: A new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87–96.
12.
Seyedin EM, Kung VT, Daniloff YN, Hesley RP, Gomez B, Nielsen LA, et al: Immunoassay for urinary pyridinoline: The new marker for bone resorption. J Bone Miner Res 1993;8:635–641.
13.
Risteli J, Elonaa I, Niemi S, Novamo A, Risteli L: Radioimmunoassay of type I collagen: A new serum marker of bone collagen degradation. Clin Chem 1993;39:635–640.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.